Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report published on Tuesday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

CNTX has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. William Blair began coverage on Context Therapeutics in a report on Monday, April 21st. They issued an “outperform” rating for the company. JMP Securities assumed coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price on the stock. Finally, Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Stock Down 0.5 %

Shares of CNTX stock opened at $0.86 on Tuesday. The firm has a market capitalization of $77.37 million, a P/E ratio of -0.95 and a beta of 2.18. Context Therapeutics has a twelve month low of $0.55 and a twelve month high of $2.75. The stock’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $1.18.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. As a group, equities research analysts expect that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of large investors have recently bought and sold shares of the business. State Street Corp lifted its stake in shares of Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares during the period. Franklin Resources Inc. bought a new stake in Context Therapeutics in the third quarter worth approximately $3,689,000. Blue Owl Capital Holdings LP lifted its stake in Context Therapeutics by 17.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock valued at $6,676,000 after buying an additional 946,638 shares during the period. Walleye Capital LLC boosted its holdings in shares of Context Therapeutics by 51.7% during the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock worth $175,000 after buying an additional 56,651 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $94,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.